Amarin's First Amendment Victory Could Cut Both Ways For Industry
This article was originally published in The Tan Sheet
Executive Summary
Companies will have to weigh prospect of freer discussion with health care providers about off-label uses with the risk that FDA and the courts will not see their statements as truthful and non-misleading.